BeiGene, Ltd. American Depositary SharesBGNE
BGNE
About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Employees: 9,000
–
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$260
Avg. target
$280
High target
$300
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Sean Laaman 0 / 0 met price target | $300 | Overweight Assumed | 3 Dec 2024 |
TD Cowen Yaron Werber 38% 1-year accuracy 6 / 16 met price target | $260 | Buy Maintained | 13 Nov 2024 |
Financial journalist opinion
Neutral
Zacks Investment Research
2 weeks ago
BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?
BeiGene (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Business Wire
4 weeks ago
BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
BASEL, Switzerland--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1st. This appointment will enhance the Company's commitment to bring impactful medicines to more patients across Europe. “We are pleased to welcome Giancarlo to BeiGene in what continues to be a transformativ.
Neutral
Business Wire
1 month ago
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose t.
Neutral
Business Wire
1 month ago
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. “As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformati.
Neutral
Business Wire
1 month ago
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, whi.
Neutral
Business Wire
1 month ago
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through continued clinical success with BRUKINSA® (zanubrutinib) and promising advancements in.
Neutral
Business Wire
2 months ago
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL.
Neutral
Business Wire
2 months ago
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company's R&D leadership team will provide an update on BeiGene's innovative portfolio and pipeline, focusing on key presentations at the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium. Th.
Positive
Seeking Alpha
2 months ago
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US
BeiGene's TEVIMBRA was just approved by the European Commission. The drug is poised to enter the EU and just reached the US market in October. BeiGene's revenue per share has grown significantly, with TEVIMBRA and BRUKINSA poised to drive the company towards profitability within 12-18 months. Analysts project BeiGene's revenues to reach $4.64 billion next year. On projected profitability the company is a strong buy with a 12-month price target of $293/share.
Neutral
Business Wire
2 months ago
European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. “Patients diagnosed with advanced gastric and esophageal cancers confront.
Charts implemented using Lightweight Charts™